Posts

Showing posts with the label Aptamers Market 2030

Aptamers Market Size Is Anticipated To Reach USD 10.88 Billion By 2030

Image
  San Francisco, 16 May 2023:  The Report   Aptamers Market  Size, Share & Trends Analysis Report By Type (Nucleic Acid, Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Region, And Segment Forecasts, 2023 - 2030 The global aptamers market size is expected to reach USD 10.88 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 24.54% from 2023 to 2030.  The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer,...

Aptamers Market Size Is Anticipated To Reach USD 126.8 Million By 2030

Image
  San Francisco, 8 Dec 2022:  The Report  Aptamers Market  Size, Share & Trends Analysis Report By Type (Nucleic Acid (DNA, RNA, XNA), Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Technology, by End-user, By Region, And Segment Forecasts, 2022 - 2030 The global aptamers market size is expected to reach USD 10.9 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 23.5% from 2022 to 2030. The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such a...